MAYNF (Mayne Pharma Group) 6-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAYNF Mayne Pharma Group Ltd MAYNF
56 GF Score
Price $2.31
GF Value $3.54
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group 6-Month Share Buyback Ratio?

Mayne Pharma Group MAYNF 56 6-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 56/100 and a GF Value™ of $3.54 (Possible Value Trap). The stock has 3 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Mayne Pharma Group's current 6-Month Share Buyback Ratio was 0.00%.


Mayne Pharma Group  (OTCPK:MAYNF) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Mayne Pharma Group 6-Month Share Buyback Ratio Related Terms


MAYNF vs MCK, COR, CAH: 6-Month Share Buyback Ratio Comparison

For the Medical Distribution subindustry, Mayne Pharma Group's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group 6-Month Share Buyback Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's 6-Month Share Buyback Ratio falls into.


MAYNF
56GF Score
Mayne Pharma Group Ltd MAYNF
6-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group 6-Month Share Buyback Ratio Calculation

Mayne Pharma Group's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Jun. 2025 ) - Shares Outstanding (EOP) (Dec. 2025 )) / Shares Outstanding (EOP) (Jun. 2025 )
=(81.246 - 81.246) / 81.246
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 6-Month Share Buyback Ratio of 0.00 mean?
Mayne Pharma Group (MAYNF) has a 6-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Mayne Pharma Group and its competitors.
Is Mayne Pharma Group's 6-Month Share Buyback Ratio too high?
Mayne Pharma Group's current 6-Month Share Buyback Ratio is 0.00. Overall, Mayne Pharma Group has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's 6-Month Share Buyback Ratio compare to MCK and COR?
Mayne Pharma Group's 6-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Share Buyback Ratio for a Medical Distribution company?
A good 6-Month Share Buyback Ratio depends on the Medical Distribution industry context. However, 6-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Share Buyback Ratio mean?
A high 6-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Mayne Pharma Group and its competitors. Mayne Pharma Group's current 6-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.54, compared to a current price of $2.31 — trading 34.7% below its estimated fair value. The current 6-Month Share Buyback Ratio is 0.00. Mayne Pharma Group's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Share Buyback Ratio calculated?
6-Month Share Buyback Ratio is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current 6-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $2.31 is trading 34.7% below its estimated GF Value™ of $3.54. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • 6-Month Share Buyback Ratio: 0.00
  • GF Value™: $3.54 vs. price of $2.31 (34.7% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
56GF Score

Get the complete analysis for MAYNF

6-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price
$3.54
GF Value